Compounds / Survodutide

Survodutide

BI 456906

Survodutide has 31 registered human trials — it is genuinely well studied. The question worth asking is what those trials were studying, because it is often not what the compound is sold for.

In short

  • 31 registered human trials exist for Survodutide.
  • Survodutide is not FDA-approved for any use.
  • What has actually been studied: chronic kidney disease, metabolic dysfunction associated steatohepatitis.
  • 4 studies are open to new participants, so this may change.
  • Last checked against ClinicalTrials.gov on 2026-07-27.
31
Registered human trials
7
Under way, incl. closed to enrolment
No
FDA approved
Pre
P1
P2
P3
Furthest stage reached

Not FDA-approved. Investigational, with fast-track designation for MASH.

What it's sold for

  • Weight loss
  • Metabolic health
  • Liver fat

What has actually been tested

  • Obesity
  • Healthy
  • Overweight
  • Diabetes Mellitus, Type 2
  • Chronic Kidney Disease
  • Liver Diseases
  • Liver Fibrosis
  • Metabolic Dysfunction Associated Steatohepatitis

Is it studied for what it's sold for?

Each claim below is matched against the condition and title fields of every registered trial. Not listed means no trial names it as a studied condition — not that it has been disproven, and not that no trial touches it indirectly.

Studied Weight loss
Studied Metabolic health
Studied Liver fat

Every trial on record

Every registered human study we can find for Survodutide. Click any ID to read the original record — we would rather you checked us than trusted us.

Trial IDTitleConditionPhaseStatusEnrolled
NCT07206290 Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease Chronic Kidney Disease Phase 2 Not yet recruiting 120
NCT06632457 LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis Metabolic Dysfunction Associated Steatohepatitis Phase 3 Recruiting now 1590
NCT06632444 LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis Phase 3 Recruiting now 1800
NCT07407348 A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Healthy, Obesity Phase 1 Recruiting now 80
NCT06352424 A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity Obesity Phase 1 Completed 23
NCT05751226 A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906 Healthy, Obesity Phase 1 Completed 88
NCT06772532 A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the Body Healthy Phase 1 Completed 30
NCT05896384 A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood Healthy Phase 1 Completed 32
NCT06492135 A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the Body Overweight, Obesity Phase 1 Completed 30
NCT04771273 A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) Non-alcoholic Steatohepatitis (NASH) Phase 2 Completed 295
NCT06214741 A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight Obesity, Overweight Phase 3 Completed 307
NCT06176365 A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease Obesity Phase 3 Completed 274
NCT06066515 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight Obesity Phase 3 Completed 726
NCT03591718 A Study to Test Different Doses of BI 456906 in Patients With Obesity Obesity Phase 1 Completed 131
NCT05296733 A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906 Healthy, Liver Diseases Phase 1 Completed 82
NCT04384081 A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2 Healthy Phase 1 Completed 37
NCT06564441 A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity Overweight, Obesity Phase 1 Completed 34
NCT04667377 A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight Obesity Phase 2 Completed 387
NCT06309992 A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD) Obesity, Non-Alcoholic SteatoHepatitis (NASH) Phase 3 Completed 218
NCT05421338 A Study in Healthy Men to Test How BI 456906 is Processed in the Body Healthy Phase 1 Completed 6
NCT06077864 A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) Obesity Phase 3 Completed 5531
NCT06352411 A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems Healthy, Renal Impairment Phase 1 Completed 42
NCT07071974 A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body Healthy Phase 1 Completed 16
NCT06200467 A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or Obesity Overweight, Obesity Phase 1 Completed 110
NCT04153929 A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. Diabetes Mellitus, Type 2 Phase 2 Completed 413
NCT06066528 A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight Obesity, Diabetes Mellitus, Type 2 Phase 3 Completed 755
NCT07413913 A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector Healthy, Obesity Phase 1 Completed 56
NCT03175211 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers Healthy Phase 1 Completed 20
NCT06745284 A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity Obesity Phase 1 Running, closed to new participants 64
NCT05202353 A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver Obesity Phase 1 Running, closed to new participants 29
NCT07221591 A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the Body Healthy Phase 1 Running, closed to new participants 100
—Read this
A trial count is not a verdict
These numbers describe how much has been formally studied in humans, not whether something works or is safe for you. A compound can be tested for one condition and sold for another — which is usually the story. This page is automated aggregation from public registries; no physician has reviewed it. Take anything here to a clinician.

Why sources disagree on this number

Different sites publish different counts for Survodutide because they are answering different questions. Here is every way of counting the same set of studies, so you can see which rule produces which number.

31
Registered human trials the number we publish
Interventional studies in people, listed on ClinicalTrials.gov, at any status.
24
Completed
Registered trials whose status is "completed".
7
Still running
Recruiting, not yet recruiting, or active.
0
Stopped early
Terminated, withdrawn, or suspended.
31
With a stated phase
Registered trials tagged Phase 1-4.
15
100+ participants
Registered trials enrolling at least 100 people.
0
Observational studies
Studies that watch rather than intervene.
You may see a lower number than 31.

Sources that count only completed studies get 24. We count registered trials at any status, because a trial that is recruiting is still a real trial and is the thing most likely to change this page. Neither number is wrong; they answer different questions.

Which number should you use?

For "how much human evidence exists", 31 is the honest answer, with the caveat that 24 have actually finished. Every trial is listed on this page with its ID — if you disagree with how we count, you can recount it yourself in about a minute.

Common questions about Survodutide

How many human trials does Survodutide have?

31. That is the number of registered interventional human studies we can find, each listed on this page with a link to its original record.

Is Survodutide FDA approved?

No. Survodutide is not approved by the FDA for any indication. Compounded or "research use only" preparations are not FDA-approved and receive no premarket review for safety, effectiveness, or manufacturing quality.

What is Survodutide actually being tested for?

Registered studies cover: chronic kidney disease, metabolic dysfunction associated steatohepatitis, metabolic dysfunction associated steatohepatitis (mash). Compare that to what it is marketed for — the two lists are often different, which is the whole point of this page.

Where does this data come from?

ClinicalTrials.gov, the US public registry of clinical studies. We count interventional human studies only — observational studies are not evidence of effect. Every trial on this page links to its original record so you can check us rather than trust us.

Get told when this changes

One email a week: what moved in the research, and which claims the record doesn't support. Free, and you can leave in one click.